ArticleHereditary cancer in clinical practice2011
Drug therapy for hereditary cancers.
Article in Hereditary cancer in clinical practice, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Predictive Genetic Testing in the Cancer Management and Prevention.Journal of cancer science and clinical therapeutics · 2025Article
- Diagnosing hereditary cancer predisposition in men with prostate cancer.Genetics in medicine : official journal of the American College of Medical Genetics · 2020Article
- Pancreatic acinar cell carcinoma is associated withCancer biology & therapy · 2019Review
- Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines.Drugs in R&D · 2017Article
- Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study.Oncotarget · 2017Article
- Treatment strategies for DNA repair-deficient prostate cancer.Expert review of clinical pharmacology · 2017Review
- Familial risk for lung cancer.Oncology letters · 2017Article
- Cytotoxic and targeted therapy for hereditary cancers.Hereditary cancer in clinical practice · 2016Review
- Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec.Current oncology (Toronto, Ont.) · 2015Article
- High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation.Medical oncology (Northwood, London, England) · 2015Article
- Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.Medical oncology (Northwood, London, England) · 2014Article
- Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations.Molecular and cellular biochemistry · 2014Article
- Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.Medical oncology (Northwood, London, England) · 2014Article
- Genetics of childhood-onset schizophrenia.Child and adolescent psychiatric clinics of North America · 2013Review
- Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer.Medical oncology (Northwood, London, England) · 2013Article
- Systemic treatment for hereditary cancers: a 2012 update.Hereditary cancer in clinical practice · 2013Article
- Role of Breast Surgery in BRCA Mutation Carriers.Breast care (Basel, Switzerland) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumors arising in patients with hereditary cancer syndromes may have distinct drug sensitivity as compared to their sporadic counterparts. Breast and ovarian neoplasms from BRCA1 or BRCA2 mutation carriers are characterized by deficient homologous recombination (HR) of DNA, that makes them particularly sensitive to platinum compounds or inhibitors of poly (ADP-ribose) polymerase (PARP). Outstandingly durable complete responses to high dose chemotherapy have been observed in several cases of BRCA-related metastatic breast cancer (BC). Multiple lines of evidence indicate that women with BRCA1-related BC may derive less benefit from taxane-based treatment than other categories of BC patients. There is virtually no reports directly assessing drug response in hereditary colorectal cancer (CRC) patients; studies involving non-selected (i.e., both sporadic and hereditary) CRC with high-level microsatellite instability (MSI-H) suggest therapeutic advantage of irinotecan. Celecoxib has been approved for the treatment of familial adenomatous polyposis (FAP). Hereditary medullary thyroid cancers (MTC) have been shown to be highly responsive to a multitargeted tyrosine kinase inhibitor vandetanib, which exerts specific activity towards mutated RET receptor. Given the rapidly improving accessibility of DNA analysis, it is foreseen that the potential predictive value of cancer-associated germ-line mutations will be increasingly considered in the future studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.